Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases.

Loriot Y, Pagliaro L, Fléchon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Malhaire JP, Linassier C, Habibian M, Martin AL, Journeau F, Reckova M, Logothetis C, Laplanche A, Le Teuff G, Culine S, Fizazi K.

Eur J Cancer. 2017 Dec;87:140-146. doi: 10.1016/j.ejca.2017.09.029. Epub 2017 Nov 14.

PMID:
29149760
2.

Differences in Incidence and Biological Characteristics of Breast Cancer between Roma and Non-Roma Patients in Slovakia.

Reckova M, Mardiak J, Plank L, Vulevova M, Cingelová S, Mego M.

Klin Onkol. Winter 2017;30(1):48-54. doi: 10.14735/amko201748.

PMID:
28185465
3.

Differences in Age-distribution, Oncological Diagnoses and Stage in Roma and Non-Roma Cancer Patients Registered at the Outpatient Oncology Department Poprad in 2014 and 2015 - a Retrospective Study.

Reckova M, Mardiak J, Beniak J, Kakalejcik M, Medvecova L, Cingelová S, Mego M.

Klin Onkol. Winter 2017;30(1):41-47. doi: 10.14735/amko201741.

PMID:
28185464
4.

Phase II study of everolimus in refractory testicular germ cell tumors.

Mego M, Svetlovska D, Miskovska V, Obertova J, Palacka P, Rajec J, Sycova-Mila Z, Chovanec M, Rejlekova K, Zuzák P, Ondrus D, Spanik S, Reckova M, Mardiak J.

Urol Oncol. 2016 Mar;34(3):122.e17-22. doi: 10.1016/j.urolonc.2015.10.010. Epub 2015 Nov 21.

PMID:
26612480
5.

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.

du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidziński M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjørge L, Lortholary A, Sailer MO, Merger M, Harter P; AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium.

Lancet Oncol. 2016 Jan;17(1):78-89. doi: 10.1016/S1470-2045(15)00366-6. Epub 2015 Nov 16.

PMID:
26590673
6.

Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study.

Mego M, Chovanec J, Vochyanova-Andrezalova I, Konkolovsky P, Mikulova M, Reckova M, Miskovska V, Bystricky B, Beniak J, Medvecova L, Lagin A, Svetlovska D, Spanik S, Zajac V, Mardiak J, Drgona L.

Complement Ther Med. 2015 Jun;23(3):356-62. doi: 10.1016/j.ctim.2015.03.008. Epub 2015 Apr 4.

PMID:
26051570
7.

Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.

Fizazi K, Pagliaro L, Laplanche A, Fléchon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Malhaire JP, Linassier C, Habibian M, Martin AL, Journeau F, Reckova M, Logothetis C, Culine S.

Lancet Oncol. 2014 Dec;15(13):1442-50. doi: 10.1016/S1470-2045(14)70490-5. Epub 2014 Nov 13.

8.

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.

Lang I, Brodowicz T, Ryvo L, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Messinger D, Zielinski C; Central European Cooperative Oncology Group.

Lancet Oncol. 2013 Feb;14(2):125-33. doi: 10.1016/S1470-2045(12)70566-1. Epub 2013 Jan 10.

PMID:
23312888
9.

Sunitinib in patients with cisplatin-refractory germ cell tumors.

Reckova M, Mego M, Sycova-Mila Z, Obertova J, Svetlovska D, Mardiak J.

Onkologie. 2012;35(7-8):455-6. doi: 10.1159/000341079. Epub 2012 Jul 3. No abstract available.

10.

Small-cell carcinoma of the ovary with breast metastases: a case report.

Reckova M, Mego M, Rejlekova K, Sycova-Mila Z, Obertova Z, Mardiak J.

Klin Onkol. 2010;23(1):43-5.

PMID:
20192073
11.

Kinetics of tumor marker decline as an independent prognostic factor in patients with relapsed metastatic germ-cell tumors.

Mego M, Rejlekova K, Reckova M, Sycova-Mila Z, Obertova J, Rajec J, Mardiak J.

Neoplasma. 2009;56(5):398-403.

PMID:
19580341
12.

Treatment of hemodialyzed patient with sunitinib.

Reckova M, Kakalejcik M, Beniak J.

Ann Oncol. 2009 Feb;20(2):392-3. doi: 10.1093/annonc/mdn734. Epub 2009 Jan 8. No abstract available.

PMID:
19136449
13.

Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malate.

Hahn NM, Reckova M, Cheng L, Baldridge LA, Cummings OW, Sweeney CJ.

J Clin Oncol. 2009 Jan 20;27(3):460-3. doi: 10.1200/JCO.2008.19.9380. Epub 2008 Dec 8. No abstract available.

PMID:
19064958
14.

Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma.

Mego M, Reckova M, Obertova J, Sycova-Mila Z, Brozmanova K, Mardiak J.

Ann Oncol. 2007 Nov;18(11):1906-7. No abstract available.

PMID:
17993633
15.

Paclitaxel, bleomycin, etoposide, and cisplatin (T-BEP) as initial treatment in patients with poor-prognosis germ cell tumors (GCT): a phase II study.

Mardiak J, Sálek T, Sycová-Milá Z, Obertová J, Recková M, Mego M, Hlavatá Z, Brozmanová K, Risnyovzská Z, Svetlovská D, Koza I.

Neoplasma. 2007;54(3):240-5.

PMID:
17447857
16.

Bevacizumab in a growing teratoma syndrome. Case report.

Mego M, Recková M, Sycova-Mila Z, Obertova J, Brozmanova K, Salek T, Mardiak J.

Ann Oncol. 2007 May;18(5):962-3. Epub 2007 Apr 13. No abstract available.

PMID:
17434900
17.

Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study.

Mardiak J, Sálek T, Sycová-Milá Z, Obertová J, Hlavatá Z, Mego M, Recková M, Koza I.

Neoplasma. 2005;52(6):497-501.

PMID:
16284696
18.

Optical mapping of electrical activation in the developing heart.

Sedmera D, Reckova M, Rosengarten C, Torres MI, Gourdie RG, Thompson RP.

Microsc Microanal. 2005 Jun;11(3):209-15.

PMID:
16060973
19.

Gemcitabine plus cisplatine and paclitaxel (GCP) in second-line treatment of germ cell tumors (GCT): a phase II study.

Mardiak J, Sálek T, Sycová-Milá Z, Obertová J, Hlavatá Z, Mego M, Recková M, Koza I.

Neoplasma. 2005;52(3):243-7.

PMID:
15875087
20.

Developmental transitions in electrical activation patterns in chick embryonic heart.

Sedmera D, Reckova M, Bigelow MR, Dealmeida A, Stanley CP, Mikawa T, Gourdie RG, Thompson RP.

Anat Rec A Discov Mol Cell Evol Biol. 2004 Oct;280(2):1001-9.

Supplemental Content

Loading ...
Support Center